PDCD1 and hepatocellular carcinoma: There is no head-to-head comparison of various immunotherapy regimens in advanced HCC; however, network meta-analyses suggest the superiority of combination immunotherapy approaches over PD-1 monotherapy and TKIs, reinforcing the importance of first-line therapy in advanced HCC [45].